Clinical Trial

Xeomin® and Gait Related Mobility After Stroke

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of the present pilot study is to evaluate the association between change in gait related mobility in ambulatory male and female adult hemiparetic patients before and 4-6-weeks after Xeomin® injection into the upper limb, using two standardized tests of physical function in outpatient rehabilitation that are widely used; the 10-meter walk test and the timed 'up and go' test (TUG).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-05-27; most recent amendment 2025-11-19.
Trial Details
NCT Number NCT04908423
Lead Sponsor Wake Forest University Health Sciences
Collaborators: Merz Pharmaceuticals GmbH
Conditions Stroke
Enrollment 20 participants
Start Date 2021-10-19
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-25